IN190564B - - Google Patents
Info
- Publication number
- IN190564B IN190564B IN334MU2001A IN190564B IN 190564 B IN190564 B IN 190564B IN 334MU2001 A IN334MU2001 A IN 334MU2001A IN 190564 B IN190564 B IN 190564B
- Authority
- IN
- India
Links
Classifications
- 
        - C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
 
- 
        - C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
 
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| IN334MU2001 IN190564B (en:Method) | 2001-04-11 | 2001-04-11 | |
| PCT/IN2001/000110 WO2002083637A1 (en) | 2001-04-11 | 2001-06-13 | Process for the production of amorphous atorvastatin calcium | 
| PCT/IN2001/000111 WO2002083638A1 (en) | 2001-04-11 | 2001-06-13 | Process for the production of atorvastatin calcium in amorphous form | 
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| IN334MU2001 IN190564B (en:Method) | 2001-04-11 | 2001-04-11 | 
Publications (1)
| Publication Number | Publication Date | 
|---|---|
| IN190564B true IN190564B (en:Method) | 2003-08-09 | 
Family
ID=11097234
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| IN334MU2001 IN190564B (en:Method) | 2001-04-11 | 2001-04-11 | 
Country Status (2)
| Country | Link | 
|---|---|
| IN (1) | IN190564B (en:Method) | 
| WO (2) | WO2002083638A1 (en:Method) | 
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium | 
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms | 
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms | 
| HUP0400381A2 (hu) | 2001-06-29 | 2004-09-28 | Warner-Lambert Company Llc | [R-(R*,R*)]-2-(4fluorfenil)-béta, delta-dihidroxi-5-(1-metiletil)-3-fenil-4-[(fenilamino)karbonil]-1H-pirrol-1-heptánsav 2:1 arányú kalciumsójának (atorvasztatin) kristályos formái | 
| CZ296967B6 (cs) * | 2002-02-01 | 2006-08-16 | Zentiva, A.S. | Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) | 
| MXPA04007995A (es) | 2002-02-19 | 2004-11-26 | Teva Pharma | Desolvatacion de solvatos de hemicalcio de atorvastatina. | 
| GB0218781D0 (en) | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process | 
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process | 
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin | 
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin | 
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin | 
| AU2003247327A1 (en) * | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form | 
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos | 
| GB0324791D0 (en) | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process | 
| CZ298382B6 (cs) * | 2004-03-10 | 2007-09-12 | Zentiva, A. S. | Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace | 
| EP1727795B1 (en) * | 2004-03-17 | 2012-02-15 | Ranbaxy Laboratories Limited | Process for the production of atorvastatin calcium in amorphous form | 
| JP2007536373A (ja) | 2004-05-05 | 2007-12-13 | ファイザー・プロダクツ・インク | アトルバスタチンの塩形態 | 
| JP2008506764A (ja) | 2004-07-20 | 2008-03-06 | ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー | [R−(R*,R*)]−2−(4−フルオロフェニル)−β、δ−ジヒドロキシ−5−(1−メチルエチル)−3−フェニル−4−[(フェニルアミノ)カルボニル]−1H−ピロール−1−ヘプタン酸カルシウム塩(2:1)の新規形態 | 
| EP1784389A4 (en) * | 2004-08-27 | 2009-03-25 | Biocon Ltd | PROCESS FOR THE PREPARATION OF AMORPHIC ATORVASTATIN CALCIUM | 
| KR20070106680A (ko) | 2004-09-30 | 2007-11-05 | 닥터 레디스 레보러터리즈 리미티드 | 비정질 아토르바스타틴 칼슘 | 
| CN101048141A (zh) * | 2004-10-28 | 2007-10-03 | 沃尼尔·朗伯有限责任公司 | 形成非晶形的阿托伐他汀的方法 | 
| WO2006048888A1 (en) * | 2004-11-01 | 2006-05-11 | Jubilant Organosys Limited | Novel process for the preparation of amorphous atorvastatin calcium salt | 
| ES2263370B1 (es) * | 2005-02-16 | 2007-12-01 | Ercros Industrial, S.A. | Atorvastatina calcica amorfa estabilizada y procedimiento para su obtencion. | 
| WO2007052296A2 (en) * | 2005-08-23 | 2007-05-10 | Kopran Research Laboratories Ltd | A process of preparing amorphous atorvastatin calcium | 
| ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. | 
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin | 
| ES2304335T3 (es) | 2005-11-21 | 2010-05-19 | Warner-Lambert Company Llc | Formas nuevas del acido (r-(r*,r*))-2-(4-fluorofenil)-b,b-dihidroxi-5-(1-metiletil)-3-fenil-4-((fenilamino)carbonil)1h-pirrol-1-heptanoico, de magnesio. | 
| WO2007061849A2 (en) * | 2005-11-23 | 2007-05-31 | Merck & Co., Inc. | Method of generating amorphous solid for water-insoluble pharmaceuticals | 
| EP2185527A2 (en) * | 2007-07-11 | 2010-05-19 | Actavis Group PTC EHF | Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium | 
| WO2009082362A1 (en) * | 2007-11-05 | 2009-07-02 | Ulkar Kimya San. Ve Tic. A.S. | A method for producing statins in pure form | 
| EP2075246A1 (en) | 2007-12-27 | 2009-07-01 | M. J. Institute of Research | A process for preparation of amorphous form of atorvastatin hemi-calcium salt | 
| WO2009090544A2 (en) * | 2008-01-16 | 2009-07-23 | Matrix Laboratories Limited | Process for producing amorphous atorvastatin calcium | 
| WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium | 
| CN113321607A (zh) * | 2020-02-28 | 2021-08-31 | 北京福元医药股份有限公司沧州分公司 | 一种阿托伐他汀钙中间体的纯化方法 | 
| CN114213270B (zh) * | 2021-12-17 | 2024-05-28 | 江苏阿尔法药业股份有限公司 | 一种利用连续流微通道反应器合成阿托伐他汀钙中间体的方法 | 
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi | 
| DK0680320T3 (da) * | 1993-01-19 | 1999-10-25 | Warner Lambert Co | Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf | 
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) | 
| IN191236B (en:Method) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd | |
| SI20425A (sl) * | 1999-12-10 | 2001-06-30 | LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. | Priprava amorfnega atorvastatina | 
- 
        2001
        - 2001-04-11 IN IN334MU2001 patent/IN190564B/en unknown
- 2001-06-13 WO PCT/IN2001/000111 patent/WO2002083638A1/en active Application Filing
- 2001-06-13 WO PCT/IN2001/000110 patent/WO2002083637A1/en active Application Filing
 
Also Published As
| Publication number | Publication date | 
|---|---|
| WO2002083637A1 (en) | 2002-10-24 | 
| WO2002083638A1 (en) | 2002-10-24 |